Tracy Schutte and Michael Yarberry are not household names, and yet they carried an entire fraud case on their shoulders. They were not government lawyers with unlimited budgets, nor professional bounty hunters. They were ordinary people who worked close enough to the billing machinery of one of the nation’s major drug retailers to see something they could not ignore. SuperValu Inc. and other health care companies, they alleged, were submitting false claims to Illinois Medicaid and the federal government for prescription drugs. According to the whistleblowers, the companies manipulated the prices used to bill public health insurers, taking advantage of arcane drug reimbursement formulas. They saw the pricing game as a way to pump extra money out of taxpayer-funded programs. A jury in 2025 agreed with them. After listening to evidence about how the companies set and reported drug prices, the jury found that false claims had been knowingly submitted. The whistleblowers had survived the brutal qui tam process: interrogatories, sealed government review, document production, motions to dismiss, years of uncertainty, and finally a trial. It appeared that the long struggle had ended in vindication. But then the legal floor dropped out. A federal district court, in a ruling after the verdict, concluded that the whistleblowers had failed to prove that the prices actually damaged the governments. Perhaps the billing numbers were wrong but never translated into net overpayment. The judge’s conclusion was cold and blunt: the whistleblowers walked away with nothing. Imagine a jury telling you that you were right, and then a judge telling you it doesn’t matter. That is the strange position they now occupy. They are appealing to the Seventh Circuit, and on Tuesday the court will consider whether corporations should pay sky-high fraud penalties in False Claims Act cases even when the government suffered no harm. This is a legal question, but underneath it is a human story about the difference between being right and being made whole.
To understand the stakes, you have to understand the strange double nature of the False Claims Act. Congress created it during the Civil War, when the Union was bleeding money to war profiteers who sold it broken rifles and failed horses. The law allowed private citizens to sue on behalf of the government and keep a share of the recovery. That mechanism is called qui tam, and it remains the most distinctive part of American fraud law. Today, the FCA is the government’s primary means to fight false billing in Medicare, Medicaid, defense contracting, and every other area where public money meets private hands. The law creates two separate remedies. The first is damages: the government can recover up to three times the amount it actually lost. The second is penalties: each false claim can generate a fixed civil penalty, a sum set by statute and adjusted for inflation. Those penalties are not small. They are currently measured in the thousands of dollars per claim. If a pharmacy chain billed Medicaid for every prescription at a false price, the number of “claims” could be enormous, and the total penalty could become many millions even before treble damages. This design is not accidental. The FCA was meant to deter the kind of fraud that is hard to calculate. The statute’s text says that a person who “knowingly presents, or causes to be presented, a false or fraudulent claim” is liable for a civil penalty “plus” treble damages. The word “plus” is crucial. In the whistleblowers’ reading, the statute does not require proof of damages before penalties can be imposed. A false claim itself is a violation. The district court, however, read the law differently. It concluded that the two men had not established that the pricing caused actual financial harm to the relevant government agencies. That is, the government may have paid the lower of multiple prices, or the reimbursement formula may have offset the false price, so no one could say with certainty that the public was poorer. Since there were no damages, the judge did not let the jury’s verdict grow into a dollar recovery. The whistleblowers now ask: what is the point of a per-claim penalty if it disappears whenever actual harm is not proven? That question is now before the Seventh Circuit.
On Tuesday, a three-judge panel of the Seventh Circuit in Chicago will hear the appeal. The phrase “will consider” is always a little too calm; in truth, the judges will be drilled by lawyers who have spent months preparing for a few minutes at the lectern. The legal question has been framed differently on each side. For Schutte and Yarberry, the issue is whether the FCA imposes a mandatory penalty for each false claim, regardless of actual damages. For SuperValu and the other defendants, the issue is whether a false claim that causes no financial injury can be a False Claims Act violation at all. The “sky-high” penalties at stake are not an exaggeration. Statutory penalties are set by a formula that has risen over time, so in current dollars each false claim can cost five figures. The government’s damages, by contrast, could be zero. The whistleblowers’ attorneys will argue that the plain language of the statute answers the question. The statute says “shall be liable” for a penalty. It does not say “liable if the government lost money.” It says “each false claim” should be punished. The district court, they will say, grafted a damages element onto a statute that did not require it. They will also remind the court that Congress had a reason: false claims can endanger public programs even if a particular price did not cause immediate loss. A false claim is a form of corruption; it erodes trust, requires oversight, and can be repeated until it finally does cause major harm. The defendants will answer that the FCA cannot be turned into a forfeiture machine. They will invoke the Due Process Clause and the Excessive Fines Clause. They will argue that a penalty with no connection to harm is punitive in the extreme and unreasonably disproportionate. They may also raise policy: every little billing mistake, every disputed pricing interpretation, every after-the-fact dispute over rounded numbers could become the basis for a massively punitive verdict. They will ask the court to imagine what the law would do to an innocent company that incurs penalties simply because a court later disagrees with a pricing judgment. It is a powerful vision, and the judges will have to navigate between text, history, and consequence.
There is no consensus among the lower courts on this issue. Some have held that actual damages are an element of a False Claims Act claim. Others have held that penalties can stand alone. The Seventh Circuit’s ruling could make a national difference. If it agrees with the whistleblowers, it may be the first court in the recent cycle to clearly say that per-claim penalties breathe even in a zero-damages case. If it agrees with SuperValu, it could create a circuit split and invite the Supreme Court to referee. The statutory context matters. In the same sentence, the FCA provides for a civil penalty “plus” three times damages. The word “plus” suggests two distinct remedies. But many courts and defense lawyers read the statute as a whole: the purpose of the law is remedial, not punitive; “damages” are the true measure of the fraud. The district court’s ruling likely rested on that view. The whistleblowers say that reading confuses the measure of damages with the element of a false claim. A false claim is the act; damages are only one possible result. The penalty is a consequence of the act, not a payment of damages. The defendants will counter that the Supreme Court has described the FCA as “quintessential” of the government’s response to fraud, and that the phrase “false or fraudulent claim” should be understood to mean a claim that causes the government to pay something it should not have paid. If there is no such payment, they argue, there has been no actual “claim” in the sense that matters. They will add that the whistleblowers themselves were in the case because they wanted a share of the recovery; if no recovery is available, a qui tam lawsuit has no reason to exist. The government’s own role is another wrinkle. Because these were claims to Illinois Medicaid and the federal government, the case is a state-federal hybrid. The federal government could have intervened but apparently let the whistleblowers carry the banner. That is common in FCA cases; the government often declines to intervene because of resources, but it can file a statement of interest. Whatever it does, if anything, may be less important than the judges’ own views of corporate liability and taxpayer justice. The word “penalties” will be central to the discussion.
The stakes go far beyond this one pair of whistleblowers. Health care fraud is typically hidden in obscure pricing formulas. When a drug company or pharmacy chain sets an average wholesale price or a spread between the reported acquisition cost and the actual discount, it can be almost impossible for a jury to trace exactly how much the government overpaid. Sometimes there is a clear overpayment; sometimes the harm is diffuse. That is why the FCA’s per-claim penalties are so significant. They are designed to punish the false statement itself, before the government must untangle every dollar. If penalties cannot be collected without a damages finding, the law loses much of its bite. It invites companies to take a calculated risk: make the false claims, and if caught, argue that the government did not prove a loss. That argument is especially tempting in prescription drug cases, where reimbursement systems are so complicated that loss is hard to compute. For whistleblowers, the decision is also practical. A qui tam lawsuit can take a decade. It can consume a career and a personal life. People like Schutte and Yarberry risk everything on the theory that the government should not pay for lies. If a jury can find liability, but the court can still send them home empty-handed, the deterrent power of the law collapses. Future whistleblowers may think twice before stepping forward. There is also a public policy argument on the other side. If penalties apply regardless of harm, the FCA’s enormous fines may force companies to settle even innocent cases, because the cost of trial is too high. This is a familiar complaint about the modern FCA. Some lawyers and judges worry that the law has become a weapon for plaintiffs’ attorneys to extract settlements from companies that made technical errors. The Seventh Circuit must decide whether that concern overrides the plain text and the statute’s original purpose. Either way, the decision will send a message to every hospital, pharmacy, and contractor billing the government. It will tell them whether a false claim is dangerous by itself, or only when the government can show that the lie made someone poorer. That message will echo far beyond this courtroom.
At the center of all this are two people whose names most people will never learn. They are probably not wealthy, not famous, and not especially accustomed to being at the podium of a federal appeals court. They have likely spent years being told that whistleblowers are essential to democracy and yet treated like troublemakers. They have survived a trial and then watched the verdict be hollowed out by a legal interpretation. Tuesday is their chance to ask the Seventh Circuit to restore the vitality of the verdict. They will not be arguing for a windfall. They will be arguing that the False Claims Act means what it says. A false claim is a false claim. A penalty is a penalty. And a jury’s finding of fraud cannot be tossed aside just because a judge thinks the government did not lose enough. The appellate judges will do their best to apply the law, and the law may lead them in either direction. But there is a human throughline that they cannot ignore. The FCA was created for people like Schutte and Yarberry: citizens who see a lie and decide to act. In 1863, the lie was about gunpowder. In 2025, it was about prescription drugs. The scale is different, but the moral architecture is the same. Government money is public money. It is not a candy jar for institutions that know how to manipulate the prices. If a company can cheat without causing a demonstrable dollar loss, it still cheated. The cost of that cheating may be invisible, but it is real. The false claim undermined the integrity of a public program. It forced community pharmacies and honest competitors to wonder whether they were the only ones playing straight. It told the government that it could not trust the numbers that came through the door. That trust, once broken, is a harm that no spreadsheet can measure. The Seventh Circuit may not say all that in its opinion. It will speak in terms of statutory interpretation, legislative intent, and precedent. But the human truth underneath is what brought the case to Chicago. On Tuesday, when the judges ask their questions and the lawyers make their points, Tracy Schutte and Michael Yarberry will be listening for one thing: a chance to turn a jury’s verdict into a meaning. Regardless of what happens, they have already done what most people would not do. But whether the law honors their sacrifice is another question. The answer could be announced in a few months. For now, they wait.